Evaluation of Hearing in Patients with Multiresistant Tuberculosis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2015 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | por eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/5783 |
Resumo: | Introduction: Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis constitute a major threat to worldwide tuberculosis control. The treatment demands the use of a therapeutic regimen in second-line drugs for a minimum period of 20 months, which includes aminoglycosides over a period of about eight months. These are associated with permanent cochleovestibular changes.Material and Methods: This cross-sectional study aims to evaluate the auditory function in individuals who completed treatment for multidrug-resistant tuberculosis (with scheme that included aminoglycosides) at the Center of Regional Reference for multidrugresistant tuberculosis located in the North of Portugal, between the years 2009 and 2012. Patients who met the inclusion criteria were submitted to tonal and vocal audiograms, otoacoustic emissions at 2000-5000 Hz frequencies, and a tympanogram.Results: Between 2009 and 2012, 27 patients were referred to the Centre of Regional Reference for multidrug-resistant tuberculosis, in the North Region of Portugal, resulting in five deaths. Of the 22 individuals invited, 11 attended. These were aged between 31 and 59 years (41 ± 10). Amikacin was used in 80% of patients. Six patients (60%) had sensorineural hearing loss.Discussion/Conclusion: The results of this study suggest the need for a more frequent audiological monitoring in patients with multidrug-resistant tuberculosis treated with aminoglycosides allowing early detect hearing loss.Keywords: Aminoglycosides; Hearing Loss/ chemically induced; Tuberculosis, Multidrug-Resistant. |
id |
RCAP_a6eb1e74517bc901c412f57dd2c91085 |
---|---|
oai_identifier_str |
oai:ojs.www.actamedicaportuguesa.com:article/5783 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Evaluation of Hearing in Patients with Multiresistant TuberculosisAvaliação da Perda Auditiva em Doentes com Tuberculose MultirresistenteIntroduction: Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis constitute a major threat to worldwide tuberculosis control. The treatment demands the use of a therapeutic regimen in second-line drugs for a minimum period of 20 months, which includes aminoglycosides over a period of about eight months. These are associated with permanent cochleovestibular changes.Material and Methods: This cross-sectional study aims to evaluate the auditory function in individuals who completed treatment for multidrug-resistant tuberculosis (with scheme that included aminoglycosides) at the Center of Regional Reference for multidrugresistant tuberculosis located in the North of Portugal, between the years 2009 and 2012. Patients who met the inclusion criteria were submitted to tonal and vocal audiograms, otoacoustic emissions at 2000-5000 Hz frequencies, and a tympanogram.Results: Between 2009 and 2012, 27 patients were referred to the Centre of Regional Reference for multidrug-resistant tuberculosis, in the North Region of Portugal, resulting in five deaths. Of the 22 individuals invited, 11 attended. These were aged between 31 and 59 years (41 ± 10). Amikacin was used in 80% of patients. Six patients (60%) had sensorineural hearing loss.Discussion/Conclusion: The results of this study suggest the need for a more frequent audiological monitoring in patients with multidrug-resistant tuberculosis treated with aminoglycosides allowing early detect hearing loss.Keywords: Aminoglycosides; Hearing Loss/ chemically induced; Tuberculosis, Multidrug-Resistant.Introdução: A tuberculose multirresistente e a extensivamente resistente constituem atualmente a principal ameaça ao controlo da tuberculose a nível mundial. O seu tratamento exige o uso de um esquema terapêutico com fármacos de segunda linha por um período mínimo de 20 meses, onde se incluem aminoglicosídeos durante um período de cerca de oito meses. Estes estão associados a alteraçõescocleovestibulares permanentes.Material e Métodos: Estudo transversal que pretende avaliar a função auditiva em indivíduos que terminaram tratamento por tuberculose multirresistente (com esquema que incluia aminoglicosídeos) no Centro de Referência Regional para a Tuberculose Multirresistente da Sub-Região de Saúde do Norte entre os anos de 2009 e 2012. Os doentes que preencheram os critérios de inclusão foram convocados para a realização de: exame objetivo otorrinolaringológico, audiograma tonal e vocal, otoemissões acústicas por produtos de distorção nas frequências de 2000-5000 Hz e timpanograma.Resultados: Entre 2009 e 2012 foram referenciados 27 casos para o Centro de Referência para a tuberculose multirresistente da Região Norte, tendo-se verificado cinco óbitos. Dos 22 indivíduos convocados, compareceram 11. Estes possuíam idades compreendidas entre os 31 e os 59 anos (41 ± 10). A amicacina foi usada em 80% e a capreomicina nos restantes. Seis (60%) dos utentes estudados apresentaram surdez neurossensorial. As otoemissões acústicas foram negativas em todos os doentes com hipoacúsia neurossensorial, o que confirma a sua origem coclear.Discussão/ Conclusão: Os resultados deste estudo sugerem a necessidade de existir uma monitorização audiológica mais frequente nos indivíduos com tuberculose multirresistente tratados com aminoglicosídeos permitindo detectar mais precocemente a perda auditiva.Palavras-chave: Aminoglicosídeos; Perda Auditiva; Tuberculose Multirresistente.Ordem dos Médicos2015-01-26info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/5783oai:ojs.www.actamedicaportuguesa.com:article/5783Acta Médica Portuguesa; Vol. 28 No. 1 (2015): January-February; 87-91Acta Médica Portuguesa; Vol. 28 N.º 1 (2015): Janeiro-Fevereiro; 87-911646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporenghttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/5783https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/5783/4241https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/5783/4320Ribeiro, LeandroSousa, ClaudiaSousa, AidaFerreira, CatarinaDuarte, RaquelFaria e Almeida, AntónioCondé, Arturinfo:eu-repo/semantics/openAccess2022-12-20T11:04:30Zoai:ojs.www.actamedicaportuguesa.com:article/5783Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:19:10.431994Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Evaluation of Hearing in Patients with Multiresistant Tuberculosis Avaliação da Perda Auditiva em Doentes com Tuberculose Multirresistente |
title |
Evaluation of Hearing in Patients with Multiresistant Tuberculosis |
spellingShingle |
Evaluation of Hearing in Patients with Multiresistant Tuberculosis Ribeiro, Leandro |
title_short |
Evaluation of Hearing in Patients with Multiresistant Tuberculosis |
title_full |
Evaluation of Hearing in Patients with Multiresistant Tuberculosis |
title_fullStr |
Evaluation of Hearing in Patients with Multiresistant Tuberculosis |
title_full_unstemmed |
Evaluation of Hearing in Patients with Multiresistant Tuberculosis |
title_sort |
Evaluation of Hearing in Patients with Multiresistant Tuberculosis |
author |
Ribeiro, Leandro |
author_facet |
Ribeiro, Leandro Sousa, Claudia Sousa, Aida Ferreira, Catarina Duarte, Raquel Faria e Almeida, António Condé, Artur |
author_role |
author |
author2 |
Sousa, Claudia Sousa, Aida Ferreira, Catarina Duarte, Raquel Faria e Almeida, António Condé, Artur |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Ribeiro, Leandro Sousa, Claudia Sousa, Aida Ferreira, Catarina Duarte, Raquel Faria e Almeida, António Condé, Artur |
description |
Introduction: Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis constitute a major threat to worldwide tuberculosis control. The treatment demands the use of a therapeutic regimen in second-line drugs for a minimum period of 20 months, which includes aminoglycosides over a period of about eight months. These are associated with permanent cochleovestibular changes.Material and Methods: This cross-sectional study aims to evaluate the auditory function in individuals who completed treatment for multidrug-resistant tuberculosis (with scheme that included aminoglycosides) at the Center of Regional Reference for multidrugresistant tuberculosis located in the North of Portugal, between the years 2009 and 2012. Patients who met the inclusion criteria were submitted to tonal and vocal audiograms, otoacoustic emissions at 2000-5000 Hz frequencies, and a tympanogram.Results: Between 2009 and 2012, 27 patients were referred to the Centre of Regional Reference for multidrug-resistant tuberculosis, in the North Region of Portugal, resulting in five deaths. Of the 22 individuals invited, 11 attended. These were aged between 31 and 59 years (41 ± 10). Amikacin was used in 80% of patients. Six patients (60%) had sensorineural hearing loss.Discussion/Conclusion: The results of this study suggest the need for a more frequent audiological monitoring in patients with multidrug-resistant tuberculosis treated with aminoglycosides allowing early detect hearing loss.Keywords: Aminoglycosides; Hearing Loss/ chemically induced; Tuberculosis, Multidrug-Resistant. |
publishDate |
2015 |
dc.date.none.fl_str_mv |
2015-01-26 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/5783 oai:ojs.www.actamedicaportuguesa.com:article/5783 |
url |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/5783 |
identifier_str_mv |
oai:ojs.www.actamedicaportuguesa.com:article/5783 |
dc.language.iso.fl_str_mv |
por eng |
language |
por eng |
dc.relation.none.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/5783 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/5783/4241 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/5783/4320 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Ordem dos Médicos |
publisher.none.fl_str_mv |
Ordem dos Médicos |
dc.source.none.fl_str_mv |
Acta Médica Portuguesa; Vol. 28 No. 1 (2015): January-February; 87-91 Acta Médica Portuguesa; Vol. 28 N.º 1 (2015): Janeiro-Fevereiro; 87-91 1646-0758 0870-399X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799130642987876352 |